Non-small-cell lung cancer (NSCLC) is an aggressive disease in which vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) are implicated in tumour growth, tumour resistance to ...
Bristol Myers Squibb (BMS) and Immatics will develop up to seven cancer cell therapies by launching a new partnership and expanding a three-year-old collaboration inked by BMS predecessor Celgene, the ...
With two cell therapies approved and three more in its pipeline, Bristol Myers Squibb is working to beef up its manufacturing capabilities for the complex, personalized, one-and-done medicines. On ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results